Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Micron Technology (MU) call put ratio 1.2 calls to 1 put into quarter results
• Rigetti Computing (RGTI) call put ratio 10.4 calls to 1 put with a focus on June 26 weekly 25 calls as share price up 2.8%
• Varonis Systems (VRNS) call put ratio 5.1 calls to 1 put with a focus on July 35, 40 and 45 calls as share price up 9%